Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 359 (9303), 294-302
- https://doi.org/10.1016/s0140-6736(02)07495-0
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”Journal of Clinical Epidemiology, 2001
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisThe Lancet, 2000
- Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable anginaEuropean Heart Journal, 1999
- Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trialThe Lancet, 1999
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsThe Lancet, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Implications of overviews of randomized trialsStatistics in Medicine, 1987
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985